Oslo

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Familial hypercholesterolaemia3 trials
• Coronary artery disease2 trials
• Melanoma2 trials
• Stroke2 trials
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Multiple sclerosis1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 39 trials
• Phase 12 trials
• Phase 21 trial

Status

• Active, not recruiting5 trials
• Completed4 trials
• Terminated3 trials

Lead sponsor

• Novartis Pharmaceuticals12 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

  NCT05838768· Phase 1· Novartis Pharmaceuticals· Source

• Recruiting

  Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

  NCT05682378· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

  NCT04417621· Phase 2· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

  NCT04652726· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study of WVT078 in Patients With Multiple Myeloma (MM)

  NCT04123418· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

  NCT01828099· Phase 3· Novartis Pharmaceuticals· Source